How would you approach a BRAF negative metastatic melanoma patient on immune checkpoint inhibitor therapy with enlarging, symptomatic brain lesions that had previously been treated with SRS?
If on pembrolizumab or nivolumab, when would you escalate to ipilimumab/nivolumab?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of North Carolina Hospitals, Chapel Hill
Answered on
Depending on the PS and medical history of the patient, would recommend moving them to ipi (3 mg/kg)/nivo (1 mg/kg) as soon as possible.
- Brent Hanks
Join for free or sign in to see the full answer